Science

SCIENCE By Kai Kupferschmidt                                                                       March 11, 2015

Researchers in Sierra Leone today started a new phase II trial of an experimental drug in Ebola patients. The first participant received an injection of the therapeutic, called TKM-Ebola, this morning at an Ebola treatment unit in Kerry Town. The trial may expand to other sites; the study team hopes to have an answer fast so that it can either move on to another drug or start a phase III study of TKM-Ebola.

Produced by Tekmira Pharmaceuticals in Burnaby, Canada, TKM-Ebola is made of synthetic, small interfering RNAs packaged into lipid nanoparticles. The RNAs target three of Ebola’s seven genes, blocking the virus’s replication. TKM-Ebola has been shown to work well in monkeys; the efficacy trial in humans is only starting now because there was not enough of the drug available earlier. Also, the RNAs have been adapted to the strain circulating at the moment.

The study does not have a placebo arm; all patients at the trial site are eligible for the drug, and researchers hope to determine whether it works by comparing them with patients treated elsewhere.

REUTERS                                                           Feb. 26, 2015

Diagnostics company Corgenix Medical Corp said on Thursday U.S. health regulators had approved its rapid Ebola test for emergency use, in response to the world's worst outbreak of the virus that killed more than 10,000 so far.

The company's ReEBOV Antigen Rapid Test, which involves putting a drop of blood on a paper strip and waiting for at least 15 minutes for a reaction, was cleared by the World Health Organization last week.

The test is less accurate than the standard test, which has a turnaround time of 12-24 hours, but is easy to perform and does not require electricity. It is able to correctly identify about 92 percent of Ebola-infected patients and 85 percent of those not infected with the virus, the WHO said.

The WHO is still assessing four or five other rapid test candidates.

Read complete story.
http://www.reuters.com/article/2015/02/26/us-health-ebola-testing-idUSKBN0LU1OO20150226

REUTERS by Stephanie Nebehay                                                             Feb. 27, 2015

GENEVA -- An independent advisory body will decide in August at the earliest on whether to recommend widespread introduction of an Ebola vaccine, depending on results of clinical trials and the epidemic's course, the World Health Organization said on Friday.

All three worst-hit countries in West Africa - Guinea, Liberia and Sierra Leone - aim to conduct phase III final-stage clinical trials of experimental vaccines.

Liberia is already testing both the GlaxoSmithKline and Merck-NewLink vaccines, while Sierra Leone and Guinea are due to announce plans soon....

WHO spokesman Christian Lindmeier, reporting on a three-day meeting of experts, told a news briefing: "Vaccine introduction is by no means a given and will depend on the results of clinical trials and recommendations from WHO's Strategy Advisory Group of Experts (SAGE) on vaccines and immunization....

Read complete story.

AFP                                                                                                                     Feb. 23, 2015
Los Angeles  - Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed Monday it was somewhat effective at saving lives if given early in the illness, but not later.

Early results from an Ebola trial using the experimental drug Avigan (favipiravir) show it is somewhat effective at saving lives if given early in the illness (AFP Photo/George Frey)

The antiviral treatment is being developed by the Japanese company Toyama Chemical, and has been shown safe and effective against some other viruses including influenza, West Nile and yellow fever.

An ongoing clinical trial in Guinea is testing the drug's use in patients with the Ebola virus, which causes severe vomiting, diarrhea and sometimes fatal bleeding.

Results from only 80 people are available so far, but they show that among those who received the drug early in their illness, 15 percent died of Ebola.

Read complete story.